Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...

As more people lose weight using medications like Ozempic, Wegovy and Mounjaro, food companies ramp up their efforts to keep ...

HONG KONG SAR - EQS Newswire - 27 March 2025 - A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (Uni-Bio Scienc ...

Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share ...

The liquid dietary supplements market accounted for $21,685.72 million in 2019, and is expected to reach $27,732.27 million by 2027, registering a CAGR of 4.0% from 2020 to 2027. According to the ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

Find insight on Novo Nordisk, Centessa Pharmaceuticals and more in the latest Market Talks covering Health Care.

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...